Last reviewed · How we verify
GALLIUM OXODOTREOTIDE
At a glance
| Generic name | GALLIUM OXODOTREOTIDE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2016 |
Approved indications
Common side effects
Key clinical trials
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Studies on Tumors of the Thyroid
- The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (PHASE1, PHASE2)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GALLIUM OXODOTREOTIDE CI brief — competitive landscape report
- GALLIUM OXODOTREOTIDE updates RSS · CI watch RSS